Not Signed In - Alpharma Data Demonstrates Alcohol Does Not Significantly Affect Pharmacokinetics Of KADIAN(R) Capsules
Sat, 10 Feb 2007 08:00 AM EST
... Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, presented results of a Phase IV study of KADIAN(R) (morphine sulfate extended-release) Capsules that demonstrate the pharmacokinetics of the long-acting opioid are not significantly affected by the consumption of alcohol. [click link for full article] ...
Related Topics
- Data & Statistics
- Data Analysis
- National Data
- Morphine ER
- Alcoholic Beverage
- Fetal Alcohol Syndrome
- Brompheniramine and Pseudoephedrine Extended Release
- Fenofibrate Capsules
- Cyanocobalamin Capsules
- Mining
- Casanthranol and Docusate Sodium
- Sulfinpyrazone Capsules
- Nizatidine capsules
- Alcohol and Youth
- Cromolyn Inhalation Capsules
- Vancomycin Capsules
- Paroxetine
- Calcium Acetate Capsules or Gelcaps
- Clindamycin Capsules
- Logging
email this page
print this page
bookmark this page
feedback on this page
